Meeting News Coverage

Viral hepatitis led to more deaths than HIV/AIDS in Europe in 2010

May 2, 2014
Viral hepatitis caused 10 times as many deaths as HIV-related cases in the European Union in 2010, according to research presented at the…
Meeting News Coverage

Simeprevir/sofosbuvir combination led to SVR12 in HCV patients

April 23, 2014
LONDON — A daily fixed-dose of simeprevir and sofosbuvir, with or without ribavirin, for 12 or 24 weeks led to a sustained virologic response…
Meeting News Coverage

Sofosbuvir/ledipasvir combination led to SVR12 in phase 3 trial

April 21, 2014
LONDON — Treatment-naive patients with hepatitis C virus infection treated with a fixed-dose combination of sofosbuvir and ledipasvir for 12 or…
Meeting News Coverage

Patients ineligible for HCV treatment due to age, comorbidities

April 20, 2014
LONDON — Age and comorbid medical conditions are the most important reasons patients are ineligible for treatment of chronic hepatitis C virus…
Meeting News Coverage

Significant correlations found between HBsAg, HBV DNA

April 16, 2014
LONDON — Hepatitis B surface antigen levels differ significantly between phases of chronic hepatitis B virus infection, according to a poster…
Meeting News Coverage

TURQUOISE-II: Three-drug regimen yields high SVR in genotype 1 cirrhotic patients

April 16, 2014
LONDON — Multitargeted therapy of ABT-450 with ritonavir, ombitasvir and dasabuvir yielded strong response rates with few discontinuations…
Meeting News Coverage

C-WORTHy: Novel therapies show promise in patients with cirrhosis, previous null responders

April 15, 2014
LONDON — Response rates to combination therapy with two novel Merck compounds with or without ribavirin were higher than 90% across a cohort of…
Meeting News Coverage

ION 2: Longer sofosbuvir/ledipasvir treatment may be unnecessary in previous failures

April 15, 2014
LONDON — Twelve weeks of treatment with the fixed-dose combination of Gilead’s sofosbuvir and ledipasvir — without ribavirin…
Meeting News Coverage

Sofosbuvir with GS-5816 shows pan-genotypic activity

April 14, 2014
LONDON — Combination therapy with sofosbuvir and the investigational compound GS-5816 yielded 12-week sustained viral response rates in…
Meeting News Coverage

Nonalcoholic fatty liver disease increased cardiovascular disease risk

April 14, 2014
LONDON — Nonalcoholic fatty liver disease contributed to increased cardiovascular risk factors, according to data from two studies presented at…